Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced that on December 1, 2025 it granted inducement restricted stock unit awards to two newly hired employees under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The awards total an aggregate of 2,200 restricted stock units, each representing the contingent right to one share of common stock. The RSUs vest in four equal annual installments beginning December 1, 2026, and vesting is conditioned on continued employment and the terms of each award agreement.

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on December 1, 2026.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com

Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com

FAQ

What did Pacira (PCRX) disclose about inducement awards on December 3, 2025?

Pacira disclosed it granted inducement restricted stock unit awards totaling 2,200 RSUs to two new employees on December 1, 2025 under its Inducement Plan.

How do the PCRX restricted stock units vest and when is the first vesting date?

The PCRX RSUs vest in four equal annual installments with the first vesting on December 1, 2026, subject to continued employment.

Were Pacira's inducement awards approved by shareholders for PCRX?

No; the People & Compensation Committee approved the awards under Nasdaq Rule 5635(c)(4) without stockholder approval.

How many employees received awards and how many shares do the PCRX RSUs represent?

Two employees received awards that together represent an aggregate of 2,200 shares of Pacira common stock.

What conditions must be met for PCRX RSU vesting to occur?

Vesting is conditioned on the employee's continued employment with Pacira and the terms of each award agreement.